RosTrace

Tag: Semaglutide

Robin Hayes

Animal Study Uncovers Distinct Metabolic Effects of Tirzepatide Versus Semaglutide

New preclinical research presented at the 2025 European Congress on Obesity (ECO) in Malaga, Spain, reveals that the anti-obesity drugs tirzepatide and semaglutide produce markedly different short-term metabolic responses in mice. While tirzepatide transiently increases energy expenditure, semaglutide initially suppresses it. Both agents, however, converge on enhanced fat oxidation and appetite suppression, with the most pronounced metabolic shifts occurring during active treatment and rapidly waning once dosing ceases.

· 5 min read

Robin Hayes

Semaglutide Approved for Cardiovascular Disease: A New Era in Treatment

Explore the recent approval of Semaglutide for cardiovascular disease management, highlighting its dual benefits in weight loss and heart health. This post delves into the implications of the SELECT study, showcasing how Semaglutide aids in reducing major cardiovascular events and improving overall health metrics. Understand the significance of this breakthrough medication, its mechanisms of action, and the future outlook for patient accessibility and advocacy in healthcare.

· 5 min read